Clinical trials for cancer are in various phases of success across the globe. pSivida Ltd, a Perth-based nanotechnology company, has announced the first human trial of their pancreatic cancer treatment BrachySil. The treatment delivers BrachySil directly to a tumour in the pancreas through an endoscopic ultrasound. This novel product, which comprises a combination of BioSilicon and the isotope 32Phosphorus, shall provide oncologists with an effective and user-friendly treatment for this disease. Pancreatic cancer has one of the lowest survival rates, with 85-90 per cent of patients being diagnosed with the inoperable form of the disease. The trial is being conducted in both Europe and Asia with a second clinical centre at the Singapore General Hospital and the National Cancer Centre Singapore.
Meanwhile, the Israeli biotech company Can-Fite BioPharma is developing a drug for liver cancer or Hepatocellular Carcinoma, currently referred to as CF102. Liver cancer attacks approx. 450,000 new patients each year and is highly frequent among people who suffer from Hepatitis B and C. This type of cancer is especially common in the Far East and no effective treatment for the disease has been discovered. Chemotherapy treatments, which are effective for other cancerous diseases have no effect on this cancer. Preclinical trials that have been conducted by the company indicate that CF102 performs well in the inhibition of liver cancer in animal models. In addition, it was proven that the A3 Adenosine receptor, which is the drug target, is over-expressed in liver cancer tumor. This comes on the heels of Can-Fite unveiling an assay that enables, by means of a blood test, to determine the receptor level before treatment initiation.
Powered by Qumana